Europe · Cardiovascular · Phase II
Which sites and PIs lead Phase II cardiovascular trials in Europe?
Hospital Ramón y Cajal and General University Hospital in Prague each appear in 22 trials. The European landscape spans 167 cardiovascular trials, including 25 coronary-disease studies and seven focused on STEMI.
across 42 whole-trial targets
Top 10 sites · all cardiovascular trials
Madrid and Prague share the lead with 22 trials each
Kraków’s John Paul II Specialist Hospital follows with 20 trials, ahead of Semmelweis University with 19. The broader cardiovascular landscape includes heart disease, stroke, vascular disease and cardiovascular prevention.
Results for distinct indications:
Coronary disease25 trialsSemmelweis University leads with 5 trials. Hospital Álvaro Cunqueiro, St. Anne’s University Hospital in Brno and John Paul II Specialist Hospital in Kraków follow with 4 each.
MI and acute coronary syndromes13 trialsHospital Álvaro Cunqueiro and St. Anne’s University Hospital in Brno share the lead with 4 trials each.
STEMI7 trialsCHU Lille, CHU Toulouse, Hospital Álvaro Cunqueiro, Rigshospitalet and St. Antonius Hospital each appear in 2 trials.
Top 10 PIs · all cardiovascular trials
Béla Merkely has the most trial listings
Béla Merkely appears in 18 trials, followed by Grzegorz Kopeć in 12. Six investigators share the next position with 10 trials each.
Results for distinct indications:
Coronary disease25 trialsBéla Merkely leads with 5 trials.
MI and acute coronary syndromes13 trialsBéla Merkely leads with 3 trials.
STEMI7 trialsThomas Engstrøm and Víctor Alfonso Jiménez Díaz share the lead with 2 trials each.
Top 10 countries · all cardiovascular trials
Spain and Germany have the broadest trial footprint
Spain appears in 64 trials and Germany in 62. Poland, Italy and France follow with 46, 44 and 43 trials.
Results for distinct indications:
Coronary disease25 trialsGermany and Poland lead with 7 trials each, followed by the Netherlands and Spain with 6 each.
MI and acute coronary syndromes13 trialsSpain leads with 6 trials. Czechia, Germany and Italy each appear in 4.
STEMI7 trialsSpain leads with 3 trials. Denmark, France and the Netherlands each appear in 2.
A multinational trial can appear in more than one country.
Average sample size · all cardiovascular trials
Planned enrollment averages 179 participants
Across 42 whole-trial targets, the median is 100 participants and the range is 10 to 1,200. Just over half of these trials plan to enroll 100 participants or fewer.
Results for distinct indications:
Coronary disease25 trials152 mean · 116 median participants 18 whole-trial targets
MI and acute coronary syndromes13 trials187 mean · 120 median participants 11 whole-trial targets
STEMI7 trials185 mean · 120 median participants 6 whole-trial targets
Targets cover the whole trial, including any countries outside Europe, and use stated enrollment caps where applicable. PULSE-MI’s goal of 378 evaluable patients is a different measure and is not pooled with enrollment targets.
Source: CTIS trial records and trial documents, with the PULSE-MI protocol. Phase II includes IIa and IIb. Coronary disease includes secondary prevention in established coronary disease. The MI/acute coronary syndrome and STEMI groups are progressively narrower groups within it.
Rankings count distinct trial listings, including proposed and historical involvement. They do not measure recruitment performance or quality. Separate hospital locations remain separate sites, PI counts include co-PIs, and ties are shown alphabetically.